Oncodesign Services has broadened its collaboration with GIP ARRONAX to enhance access to critical radionuclides, including astatine-211, for use in Targeted Radiotherapy (TRT) research. The expanded agreement builds on an existing partnership and aims to address one of the key challenges in radiopharmaceutical development—limited availability of specialised isotopes.

The collaboration will support ongoing discovery and preclinical programmes by ensuring a stable supply of radionuclides that are essential for advancing innovative cancer therapies. Among these, astatine-211 has gained increasing attention due to its strong therapeutic potential as an alpha-emitting isotope, though its short half-life and complex production requirements make it difficult to access at scale.

GIP ARRONAX, known for its expertise in producing advanced radionuclides, has already been supplying isotopes such as lead-203 and copper-64 to Oncodesign Services. With the inclusion of astatine-211 in the partnership, the two organisations aim to further strengthen research capabilities in targeted radiotherapy, where precise coordination of production, transportation and application is crucial.

The partnership is expected to accelerate preclinical research by reducing bottlenecks related to isotope availability, enabling more efficient study execution and data generation. Oncodesign Services, which specialises in translational drug development across oncology and immune-related diseases, will leverage this access to enhance its work in early-stage radiotherapy programmes.

Meanwhile, GIP ARRONAX brings extensive experience in the full development chain of radionuclides, from production and radiolabelling to clinical application support. The collaboration reflects a shared commitment to advancing next-generation therapies by integrating scientific innovation with operational efficiency.

By addressing supply constraints early in the development process, the partnership aims to support smoother progression of targeted radiotherapy candidates from preclinical stages toward clinical evaluation, ultimately contributing to improved treatment options for patients.